<DOC>
	<DOCNO>NCT00663858</DOCNO>
	<brief_summary>Benign Prostatic Hypertrophy ( BPH ) common bothersome condition age men . It characterize enlargement prostate occur human male age 50 increase prevalence age , among age 50 80 , 40 % report moderate severe urinary symptom prostatism . The aim treatment improve patient ' quality life primarily depend severity symptom BPH . Current treatment BPH benefit / risk ratio leave room improvement . For study , study medication ( Cetrorelix pamoate placebo ) administer injection buttock ( Intramuscular ) . All patient complete double-blind portion ( Week 0 52 ) eligible receive active drug open-label part study ( Week 52 90 ) .</brief_summary>
	<brief_title>Cetrorelix Pamoate Patients With Symptomatic Benign Prostatic Hypertrophy ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>Benign Prostatic Hyperplasia , base medical history Voiding symptom Urgent need prostate surgery prior surgical treatment prostate bladder Major organ dysfunction Eczema ( atopic dermatitis ) treat last 6 month Current recent treatment sexual hormone drug 5 α reductase inhibitor botulinum toxin type ( Botox ) within last 6 month prior randomization α blocker saw palmetto within last 6 week prior randomization Urologic disorder include neurogenic bladder dysfunction due diabetes mellitus document neurologic disorder , urethral stricture disease history pelvic radiation therapy History acute obstructive , infectious , neurological disorder genitourinary tract within last 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>